• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

RASSEGNE - Reviews

Volume:

Biochimica Clinica 2015; 39(4) 241-255

Pubblicato on-line:

DOI:

Scarica in PDF:

Rilevanza clinica e interpretazione dei marcatori biochimici nello scompenso cardiaco

AUTORI

Maria Franzini1, Silvia Masotti2, Concetta Prontera3, Aldo Clerico2,3 a nome del Gruppo di Studio SIBioC - Medicina di Laboratorio Marcatori Cardiaci
1Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, Università di Pisa
2Scuola Superiore Sant’Anna, Pisa
3Fondazione G. Monasterio CNR – Regione Toscana, Pisa

ABSTRACT

Clinical relevance and interpretation of biochemical markers in heart failure

Heart failure (HF) is a global problem with an estimated prevalence of 38 million patients worldwide. Both prevalence and incidence of HF increase progressively with population ageing (prevalence ≥10% in people >75 years), especially in the high-income countries. HF is considered as the fatal event of all cardiovascular disorders. Despite some progress in diagnosis and treatment, its prognosis is worse than that of most cancers. The disease is heterogeneous in its clinical presentation and the diagnosis is not based on a single test, but on a combination of the history, physical examination and appropriate investigations, including some laboratory tests. As a consequence, the accuracy of diagnosis by clinical signs alone is often inadequate, especially in the early asymptomatic stage of HF. For these reasons, there is an increasing interest in the development of new biomarkers useful for the diagnosis, prognosis and follow-up of patients with HF. The aim of this paper is to provide an overview of biomarkers recommended by international guidelines for HF, discussing their clinical impact and the interpretation of results. Furthermore, a possible strategy for the development and evaluation of novel prognostic biomarkers for HF will be suggested.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967